2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.
The dose of cetuximab must be precise otherwise it will be difficult for a patient with head and neck cancer to see results, explains Ciccolini.
It needs to be ensured that the drug is at a certain level to exert constant pressure on the target. This makes dose de-escalation difficult with this drug, but it was the best way to see responses, states Ciccolini.
Related Content: